The Global Health Innovation Alliance Accelerator

What The Global Health Innovation Alliance Accelerator does

The Global Health Innovation Alliance Accelerator (GHIAA) is a 501(c)(3) nonprofit founded in 2017 and headquartered in Research Triangle Park, Durham, North Carolina. It operates as a specialized advisory and resource organization focused on equitable access to medical products, with a particular emphasis on the access-related provisions negotiated into global health agreements. Its core product is MAPGuide, a searchable platform paired with a provision database that catalogs equitable-access language drawn from agreements involving NIH, BARDA, CEPI, WHO, and the Gates Foundation. Around MAPGuide, GHIAA has built a portfolio of complementary resources: the Equitable Access Toolkit (December 2022), the Equitable Access Glossary (November 2023), and a Vaccine Manufacturing Strategic Insights offering, alongside a Consulting Services line.

GHIAA is directed by Executive Director Julie Barnes-Weise, supported by a four-person core staff and a seven-member board drawing from the Gates Foundation, MSF Access, DNDi, GHIT Fund, Georgetown Law, and Novartis. Its primary funders and partners are the Wellcome Trust, WHO, the International Vaccine Institute (IVI), the Medicines Patent Pool, and the Licensing Executives Society (LES), with academic affiliations at Duke University and the University of Washington. The Platform is offered free to the public while consulting and strategic-insights work is delivered paid, positioning GHIAA as a hybrid advisory-and-public-goods organization.

The business model is grant-funded for the public-goods layer (MAPGuide, Toolkit, Glossary sit on free access) and fee-for-service for the advisory layer (Consulting Services and Vaccine Manufacturing Strategic Insights). The principal revenue source is multi-year grant funding from the Wellcome Trust, most recently renewed in 2025. Beyond Wellcome, GHIAA extends its reach through policy engagement — including formal comments on the NIH Intramural Research Program Access Planning Policy (January 2025) and participation in the WHO Pandemic Agreement process (August 2024) — and through training delivered via IVI vaccinology courses in Seoul, Stockholm, and Kigali.

End-user segments are global health funders, multilateral organizations, government health agencies, pharmaceutical and biotech companies, and academic institutions operating in the access-and-licensing space.

Name

The Global Health Innovation Alliance Accelerator

Legal name

Global Healthcare Innovation Alliance Accelerator

Website

https://ghiaa.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

The Global Health Innovation Alliance Accelerator (GHIAA) is a 501(c)(3) nonprofit that builds the MAPGuide platform and related equitable-access resources to help global health funders, multilaterals, governments, and pharma negotiate and analyze access provisions in medical-product agreements.

Ownership category

akta.pro rank

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Consulting Services: GHIAA provides practical, pragmatic advice for organizations seeking to navigate the complexities of developing and implementing access plans and agreement provisions. Revenue generated from expert advisory engagements with governments, multilaterals, and foundations.
2. Platform Access (Freemium): All information on GHIAA's websites including MAPGuide platform is provided for free. The organization reserves the right to charge for future services. Current operations are primarily grant-funded.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

GHIAA is an independent nonprofit think tank and consultant that creates resources, curates information, collaborates with stakeholders, and provides expert advisory services on policies and agreement provisions that aim to achieve equitable, global access to medical products. Its primary product is the MAPGuide® Platform, a digital tool that includes a Provision Database, Equitable Access Toolkit, and Equitable Access Glossary, complemented by consulting services for organizations negotiating and implementing access provisions in global health agreements.

Product overview

The Global Health Innovation Alliance Accelerator (GHIAA) offers a suite of products and services focused on global health policy and equitable access to medical products. The core offering is the MAPGuide® Platform, a comprehensive tool for exploring analysis of global health agreements that includes a Provision Database, Equitable Access Toolkit, and Equitable Access Glossary. GHIAA also provides Consulting Services offering expert advice for access plans, provisions and policies, and produces Vaccine Manufacturing Strategic Insights. The MAPGuide Platform serves as the central resource, supported by specialized sub-products including the Equitable Access Toolkit for R&D funders, the Equitable Access Glossary for terminology reference, and the Provision Database for analyzing agreement terms. The platform and resources are developed with support from the Wellcome Trust.

Differentiator

Problem solved

Functional benefit

Brands

• MAPGuide: A platform for exploring analysis of global health agreements, particularly those that seek to ensure equitable access to medical products. Includes Provision Database, Equitable Access Toolkit, and Equitable Access Glossary.

Products and services

• MAPGuide® Platform A comprehensive online platform for exploring analysis of global health agreements, particularly those that seek to ensure equitable access to medical products. The platform includes a searchable Provision Database, the Equitable Access Toolkit, and the Equitable Access Glossary, and is freely accessible to global health stakeholders.
• Consulting Services Expert advisory services for organizations seeking to increase access to medical products, including practical, pragmatic advice for navigating the complexities of developing and implementing access plans, agreement provisions, and policies. Engagements are typically with governments, multilaterals, and foundations.
• Vaccine Manufacturing Strategic Insights Publications, events, and strategic insights focused on the role of agreement terms in supporting increased and accelerated access for underserved populations, both for COVID-19 vaccines and for future vaccine needs.
• Equitable Access Toolkit A standalone resource (part of the MAPGuide platform) designed to support medical product R&D funders with the translation of equitable access policies into funding agreement provisions that have meaningful and measurable impact.
• Equitable Access Glossary A curated collection of commonly used terms in policies, negotiations and agreements in the global public health field, designed to help stakeholders use consistent terminology for equitable access discussions.

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Licensing Executives Society (LES) USA & CanadaminorStrategic or Co-development Partner · 21 October 2024Julie Barnes-Weise moderated a workshop at LES Annual Meeting titled 'Bridging the Gap – Licensing Medical Technologies for Innovation and Global Equitable Access' with panel members from the global health licensing community.
• International Vaccine Institute (IVI)coreStrategic or Co-development Partner · 2 September 2024GHIAA Executive Director Julie Barnes-Weise participated in IVI's 23rd Annual International Vaccinology Course (IVC) in Seoul, Stockholm, and Kigali. GHIAA also contributed to IVI's Global Training Hub for Biomanufacturing course with a lecture on Partnerships & Equitable Access to Vaccines.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 30 August 2024GHIAA provides recommendations and analysis on the WHO Pandemic Agreement negotiations, particularly regarding Article 9 (R&D), Article 11 (technology transfer), and Article 13bis (procurement). GHIAA's MAPGuide platform is presented as a resource to support ongoing INB discussions.
• Medicines Patent PoolcoreStrategic or Co-development PartnerGHIAA collaborated with the Medicines Patent Pool on responding to the NIH Request for Information on access planning policy. GHIAA's Equitable Access Toolkit and MAPGuide resources are referenced as useful tools for potential NIH licensees.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Drugs for Neglected Diseases initiative (DNDi): Nonprofit R&D organization developing treatments for neglected diseases. Shares GHIAA's mission on equitable access to medical products; board member Thi Hanh Cao is DNDi's Director of External Relations, evidencing direct overlap.
• Coalition for Epidemic Preparedness Innovations (CEPI): Global partnership funding vaccine development against epidemic threats. Operates in the same pandemic preparedness and equitable access space as GHIAA; GHIAA's Development Director Bridie Telford was previously CEPI's contracts manager.
• Access to Medicine Foundation: Nonprofit that ranks and incentivizes pharmaceutical companies on access to medicine. Shares GHIAA's mission of improving equitable access through policy and corporate behavior influence, with a research and benchmarking model rather than platform/tools.
• International Vaccine Institute (IVI): International organization dedicated to vaccine development and delivery for global health. Active GHIAA partner—GHIAA's Executive Director contributes to IVI's vaccinology courses and biomanufacturing training—operating in the same vaccine access and policy space.
• Mécins Sans Frontiéres (MSF) Access Campaign: MSF's access-to-medicines initiative pushing for policy and pricing reforms. Shares GHIAA's policy-advocacy focus on equitable access; multiple GHIAA board members (Isaac Chikwanha, Carolina Batista) have leadership backgrounds at MSF/MSF Access.
• Policy Cures Research: Independent global health think tank focused on R&D policy and financing for emerging infectious diseases and neglected conditions. Closely comparable in providing research-driven policy advice to global health funders—GHIAA's core constituency.
• Global Health Technologies Coalition (GHTC): Advocacy coalition of NGOs, academic institutions, and product development partnerships working to advance global health R&D. Operates in the same advocacy and policy space as GHIAA, with overlapping stakeholder base among funders and multilaterals.
• Medicines Patent Pool: UN-backed public health organization working to increase access to medicines through voluntary licensing and technology transfer. Directly comparable to GHIAA in mission focus on equitable access and is an active GHIAA partner on NIH access planning responses.

Broad incumbents

• PATH: Large global health nonprofit driving innovation in vaccines, drugs, and diagnostics across more than 70 countries. A broader incumbent operating across the same equitable access and medical product innovation space but with vastly greater resources and program depth.
• Wellcome Trust: Major charitable foundation funding global health research and policy. GHIAA's primary disclosed funder, so comparable as a stakeholder/ecosystem player with aligned priorities on equitable access to medical products, though operating at vastly larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/GHIAAteam
• LinkedInlinkedin.com/company/global-healthcare-innovation-alliance-accelerator

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Global Health Innovation Alliance Accelerator